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Abstract
Background: Ertapenem is a once-a-day carbapenem and has excellent activity against many gram-
positive and gram-negative aerobic, facultative, and anaerobic bacteria. The susceptibility of isolates
of community-acquired bacteremia to ertapenem has not been reported yet. The present study
assesses the in vitro activity of ertapenem against aerobic and facultative bacterial pathogens
isolated from patients with community-acquired bacteremia by determining and comparing the
MICs of cefepime, cefoxitin, ceftazidime, ceftriaxone, ertapenem, piperacillin, piperacillin-
tazobactam, ciprofloxacin, amikacin and gentamicin. The prevalence of extended broad spectrum
β-lactamases (ESBL) producing strains of community-acquired bacteremia and their susceptibility
to these antibiotics are investigated.
Methods: Aerobic and facultative bacteria isolated from blood obtained from hospitalized patients
with community-acquired bacteremia within 48 hours of admission between August 1, 2004 and
September 30, 2004 in Chang Gung Memorial Hospital at Keelung, Taiwan, were identified using
standard procedures. Antimicrobial susceptibility was evaluated by Etest according to the standard
guidelines provided by the manufacturer and document M100-S16 Performance Standards of the
Clinical Laboratory of Standard Institute. Antimicrobial agents including cefepime, cefoxitin,
ceftazidime, ceftriaxone, ertapenem, piperacillin, piperacillin-tazobactam, ciprofloxacin, amikacin
and gentamicin were used against the bacterial isolates to test their MICs as determined by Etest.
For Staphylococcus aureus isolates, MICs of oxacillin were also tested by Etest to differentiate
oxacillin-sensitive and oxacillin-resistant S. aureus.
Results:  Ertapenem was highly active in vitro against many aerobic and facultative bacterial
pathogens commonly recovered from patients with community-acquired bacteremia (128/159,
80.5 %). Ertapenem had more potent activity than ceftriaxone, piperacillin-tazobactam, or
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ciprofloxacin against oxacillin-susceptible S. aureus (17/17, 100%)and was more active than any of
these agents against enterobacteriaceae (82/82, 100%).
Conclusion: Based on the microbiology pattern of community-acquired bacteremia, initial empiric
treatment that requires coverage of a broad spectrum of both gram-negative and gram-positive
aerobic bacteria, such as ertapenem, may be justified in moderately severe cases of community-
acquired bacteremia in non-immunocompromised hosts.
Background
Ertapenem is a once-a-day parenteral β-lactam antimicro-
bial agent [1-6]. Preclinical in vitro studies have shown
that this structurally unique carbapenem has excellent
activity against many gram-positive and gram-negative
aerobic, facultative, and anaerobic bacteria that, in gen-
eral, are associated with community-acquired infections
[1-6]. However, it has minimal activity against Pseu-
domonas aeruginosa, Acinetobacter species, and enterococci
[1-6], and these pathogens usually are associated with
nosocomial infections. Recent antimicrobial susceptibil-
ity surveillance data indicate that the organisms causing
intra-abdominal, skin and soft tissue, and urinary tract
infections and community-acquired pneumonia are
highly susceptible to ertapenem in vitro [7-17]. However,
the susceptibility of isolates of community-acquired bac-
teremia to ertapenem has not yet been reported. The
objective of the present study is to assess the in vitro activ-
ity of ertapenem against aerobic and facultative bacterial
pathogens isolated from patients with community-
acquired bacteremia by determining and comparing the
MICs of cefepime, cefoxitin, ceftazidime, ceftriaxone,
ertapenem, piperacillin, piperacillin-tazobactam, cipro-
floxacin, amikacin and gentamicin. In addition, the prev-
alence of ESBL producing strains of community-acquired
bacteremia and their susceptibility to these antibiotics are
investigated.
Methods
Chang Gung Memorial Hospital at Keelung is an 850-
bed(including 55 ICU beds) teaching hospital offering a
broad range of services in serving the healthcare needs of
about 500,000 residents in northern Taiwan. It has
approximately 21,000 admissions per year and mean
duration of hospitalization of 8.2 days. Aerobic and facul-
tative bacteria isolated from blood obtained from hospi-
talized patients with community-acquired bacteremia
within 48 hours of admission between August 1, 2004
and September 30, 2004 in Chang Gung Memorial Hos-
pital at Keelung were identified using standard proce-
dures. Community-acquired bacteremia was diagnosed
when clinically significant bacterial pathogens were iso-
lated from the blood of hospitalized patients with fever of
38.0°C within 48 hours of admission and without
admission in past two weeks. Cases with only one blood
culture bottle positive for normal skin flora such as coag-
ulase-negative staphylococci, Staphylococcus epidermidis, Sta-
phylococcus saprophyticus and corynebacterium  spp. were
excluded. All bacillus,  micrococcus  and  propionibacterium
isolates which were considered contaminants and anaero-
bic bacteria were excluded. Clinically significant aerobic
bacterial isolates were collected and stored in tryptic soy
broth and frozen at -70°C.
Antimicrobial susceptibility was evaluated by Etest
according to the standard guidelines provided by the
manufacturer and document M100-S16 Performance
Standards of the Clinical Laboratory of Standard Institute
(CLSI). Antimicrobial agents mentioned above were used
against the bacterial isolates to test their MICs as deter-
mined by Etest (AB Biodisk, Solna, Sweden). The antimi-
crobial agents used for each bacteria strain vary from three
to eleven (Table 1). For S. aureus isolates, MICs of oxacil-
lin were also tested by Etest to differentiate oxacillin-sen-
sitive and oxacillin-resistant S. aureus. Detection of mecA
gene using primers mecA1 GTA GAA ATG ACT GAACGT
CCG ATA A and mecA2 CCA ATT CCA CAT TGT TTC GGT
CTA A with polymerase chain reaction method and MICs
of amoxicillin/clavulanic acid with Etest for ORSA isolates
were also performed using standard procedure. E test was
performed on Mueller-Hinton agar (pneumococci  and
streptococci: blood agar). The MICs were read at the point
where the inhibition ellipse intersected the scale on the
strip after incubation at 35°C for 24 hours. Macrocolonies
within the ellipse were regarded as significant growth
whereas microcolonies could be neglected.
For quality control, standard control strains were included
with each test run. The following organisms with accepta-
ble MICs (µg/ml) limits were included as control strains
according to CLSI M7-A7 [18]: S. aureus ATCC 29213
(0.12–0.5 for ciprofloxacin, 4–16 for ceftazidime, 1–4 for
cefepime, 0.25/4-2/4 for piperacillin/tazobactam), E. coli
ATCC 25922 (0.004–0.016 for ciprofloxacin, 0.06–0.5 for
ceftazidime, 0.016–0.12 for cefepime, 1/4-4/4 for pipera-
cillin/tazobactam), P. aeruginosa ATCC 27853 (0.25–1 for
ciprofloxacin, 1–4 for ceftazidime, 1–8 for cefepime, 1/4-
8/4 for piperacillin/tazobactam), Streptococcus pneumoniae
ATCC 49619 (0.06–0.25 for cefepime), Enterococcus faeca-
lis ATCC 29212 (0.25–2 for ciprofloxacin, 1/4-4/4 for pip-
eracillin/tazobactam).BMC Infectious Diseases 2007, 7:79 http://www.biomedcentral.com/1471-2334/7/79
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According to CLSI M7-A7, MIC(µg/ml) breakpoints of
susceptibility for each type of bacteria were listed in Table
1.
S. aureus isolates with oxacillin MIC of 2 µg/ml were
regarded as oxacillin-sensitive S. aureus (OSSA), whereas
isolates with oxacillin MIC of 4 µg/ml were regarded as
oxacillin-resistant S. aureus (ORSA) according to criteria
of S. aureus susceptibility to oxacillin in CLSI document.
M7-A7 published in January 2006. Enterobacteriaceae iso-
lates with ceftazidime MIC 2 µg/ml but MIC diminished
at least 3 fold after addition of clavulanic acid were
regarded as ESBL strains.
Results and dscussion
There were 70 male and 89 female. Ages ranged from 1
year to 95 years with mean 60.9 years. There were 147
adults (age 17 years, range 22–95 years, mean 65.2
years) and 12 pediatric patients (age 16 years, range 1–
16 years, mean 3.2 years). Of the 159 cases of community-
acquired bacteremia, the most likely primary foci of origin
according to clinical manifestations are urinary tract infec-
tion 59, pneumonia 39, biliary tract infection 17, cellulitis
9, infective endocarditis 3, osteomyelitis 2, peritonitis 1,
gastroenteritis 1, and esophagitis 1. The primary foci of
origin of the remaining 27 cases of community-acquired
bacteremia are unknown. A total of 159 aerobic bacterial
pathogens from 159 patients enrolled at Chang Gung
Memorial Hospital were collected. Most (95/159, 59.7%)
of the isolates were facultative gram-negative bacilli. The
most common organism found was E. coli, which
accounted for 26.4% (42/159) of the total. There were
only seven isolates (7/159, 4.4%) with ESBLs (E. coli –
ESBL, 4; K. pneumoniae – ESBL, 3).
Figure 1 shows the distribution of ertapenam MIC values
for all bacteria isolates tested. Among all the collected iso-
lates, 128 out of 159 isolates (80.5%) were susceptible to
ertapenem (MICs 2 µg/ml) and 19.5 % was resistant
(MICs 4 µg/ml). 112 out of 159 isolates (70.4%) were
susceptible to ceftriaxone (MICs 8 µg/ml). Among the
82 enterobacteriaceae isolates, including the ESBL strains,
all (100%) were susceptible to ertapenem while 71
(86.6%) was susceptible to ceftriaxone (Additional file 1).
All seven ESBL strains including four E. coli -ESBL and
three  K. pneumoniae-ESBL isolates were susceptible to
ertapenem, ceftazidime/clavulanic acid and cefotaxime-
clavulanic acid (Additional file 1). Seven isolates of coag-
ulase-negative staphylococci were repetitively isolated from
seven patients and were thus regarded as significant iso-
lates. Three of these seven isolates were susceptible to
ertapenem (Additional file 1). Included in the ertapenem-
resistant group were enterococci, oxacillin-resistant S.
aureus, oxacillin-resistant coagulase-negative staphylococci,
P. aeruginosa and other non-fermentative gram-negative
bacilli (Table 1). Of the two ORSA isolates that were sus-
ceptible in vitro to amikacin, one was also susceptible to
ciprofloxacin and gentamicin.(Additional file 1). Antimi-
crobial activities of ertapenem and the comparator agents
against all bacteria tested are summarized in Additional
file 1. All MICs of control strains obtained with Etest were
within the acceptable range listed by CLSI M7A7.
Although most OSSA were susceptible to the majority of
agents tested, ertapenem had the most potent activity,
based on values for inhibition of 50 % (MIC50) and 90%
(MIC90) of the isolates. All isolates of OSSA were suscep-
tible to ertapenem (17/17, 100 %). Ertapenem was the
most active agent against enterobacteriaceae and demon-
strated high potency based on MIC50 and MIC90 values. All
isolates of enterobacteriaceae, including most ESBL
strains, were susceptible to ertapenem (82/82, 100%)
while not as susceptible to ceftriaxone (86.6 %). Among
these 159 isolates, there were 38 E. coli isolates of which 4
(10.5%) were ESBL strains, and 13 K. pneumoniae isolates,
of which 3 (23%) were ESBL strains. The prevalence of
enterobacteriaceae with ESBLs in community-acquired
bacteremia was 7/159, 4.4% in this study. In our hospital,
there were 877 significant isolates including fungus, aero-
bic and anaerobic bacteria causing nosocomial infections
Table 1: MIC(µg/ml) breakpoints of susceptibility for each type of bacteria
MIC Breakpoint of Susceptibility (µg/ml)
Type of  bacteria /Antibiotic FEP FOX CAZ CRO ERT PIP TAZO CIP AN GM
Staphylococci 8 8 8 8 2 16 8/4 1 16 4
Streptococci 1 8 8 8 1 8/4 1
Enterococci 8* * 8/4 1
Enterobacteriaceae 8 8 8 8 2 16 16/4 1 16 4
Non-fermenters 8 8 8 8 2 16 16/4* 1 16 4
FEP = cefepime, FOX = cefoxitin, CAZ = ceftazidime, CRO = ceftriaxone, ERT = ertapenem, PIP = piperacillin, TAZO = piperacillin-tazobactam, 
CIP = ciprofloxacin, AN = amikacin GM = gentamicin, MIC = minimal inhibitory concentrations, ≤ indicates less than or equal to.
* For P. aeruginosa, MIC susceptibility breakpoint of piperacillin-tazobactam is 64/4 µg/ml.
** There are no proposed breakpoints for ertapenem against enterococci. In this present study, 2 µg/ml was used as breakpoint for ertapenem 
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in 2006. Among these 877 nosocomial isolates in our hos-
pital in 2006, there were 151 E. coli isolates, of which 21
(14%) were ESBL strains, and 69 K. pneumoniae isolates, of
which 22 (31.8%) were ESBL strains. The overall rate of
ESBL strain among nosocomial isolates were 43/877
(4.9%). Although the overall rate of ESBL isolates among
community-acquired bacteremia (4.4%) was close to that
among nosocomial infections (4.9%), the rate of ESBL
isolates among E. coli and K. pneumoniae were still higher
in nosocomial infections. As expected, ertapenem and
ceftriaxone had minimal activity against P. aeruginosa and
enterococci. Among the nine ORSA isolates with oxacillin
MICs 4 µg/ml, two ORSA isolates were mecA gene posi-
tive with amoxicillin/clavulanic acid MICs 32 µg/ml. The
other seven ORSA isolates were mecA gene negative with
amoxicillin/clavulanic acid MICs range 8–12 µg/ml,
mean 11.4 µg/ml, indicating that mechanism of oxacillin
resistance in these seven ORSA isolates was not due to
mecA gene and was most likely due to hyperproduction of
β-lactamases [19-22]. Two of the nine ORSA isolates were
susceptible to amikacin, including one isolate that was
also susceptible in vitro to ciprofloxacin and gentamicin;
these two isolates resistant to all β-lactam antibiotics
might lack resistance gene to other classes of antibiotics
[19-22]. Based on the microbiology of community-
acquired bacteremia, empiric treatment requires coverage
of a broad spectrum of both gram-negative and gram-pos-
itive aerobic bacteria. In this in vitro study, ertapenem was
the most active of the agents evaluated against the pre-
dominant pathogens – enterobacteriaceae and S. aureus. As
anticipated, ertapenem had minimal activity against P.
aeruginosa and enterococci, which was recovered relatively
infrequently from community-acquired bacteremic infec-
tions. Because of the low frequency of isolation of P. aer-
uginosa  and doubtful pathogenicity of enterococci  in
immune competent hosts, initial empiric antimicrobial
regimens for bacteremic infections need not include
agents specifically directed against these organisms. How-
ever, if P. aeruginosa is clearly identified as a pathogen in
these patients, specific antipseudomonal coverage would
be indicated.
Conclusion
In summary, ertapenem was highly active in vitro against
many aerobic and facultative bacterial pathogens com-
monly recovered from patients with community-acquired
bacteremia. Ertapenem had more potent activity than
cefepime, cefoxitin, ceftriaxone and piperacillin-tazo-
bactam against methicillin-susceptible S. aureus and was
more active than any of these agents against enterobacte-
riaceae including strains with ESBL.
Community-acquired bacterial blood stream infections
are common in clinical practice. Septicemia secondary to
other foci of infections are caused by gram-negative and
gram-positive aerobic and facultative bacteria, although E.
coli  and  S. aureus remain the predominant pathogens.
Non-fermentative gram-negative bacteria, which tend to
be associated with nosocomial infections, are infre-
quently involved in community-acquired infections.
Based on the microbiology pattern of community-
acquired bacteremia, initial empiric treatment that
requires coverage of a broad spectrum of both gram-nega-
tive and gram-positive aerobic bacteria, such as ertap-
enem, may be justified in moderately severe cases of
community-acquired bacteremia in non-immunocom-
promised hosts. However, effect of ertapenem on the gut
flora is still a concern.
Authors' contributions
SCL designed the study, carried out the antimicrobial sus-
ceptibility studies with Etest and drafted the manuscript.
SSH and CWL participated in the antimicrobial suscepti-
bility studies. CPF participated in the design of the study.
WBS participated in the statistical analysis. LKS assisted in
the detection of mecA gene of oxacillin-resistant S. aureus
with PCR. All authors read and approved the final manu-
script.
Additional material
Additional file 1
Comparative in vitro activity of ertapenem and comparator agents against 
aerobic and facultative bacteria isolated from patients with community-
acquired bacteremia.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2334-7-79-S1.doc]
Distribution of ertapenem MIC values for aerobic and facul- tative bacteria isolated from patients with community- acquired bacteremia Figure 1
Distribution of ertapenem MIC values for aerobic and facul-
tative bacteria isolated from patients with community-
acquired bacteremia.
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